Alps Group Inc has launched a new Pharmaco-Interaction (PCI) laboratory unit under its MyGenome subsidiary in Kuala Lumpur, Malaysia. The PCI unit debuts with CYP450 inhibitory IC50 testing, covering seven major enzyme isoforms responsible for metabolizing about 90% of clinical drugs. This service targets herbal, supplement manufacturers, pharmaceutical companies, and research institutions, addressing a gap in Southeast Asia for accredited drug interaction safety testing. The move supports regulatory compliance and aims to position MyGenome as a regional reference lab for drug interaction safety science, enhancing the company's integrated biotechnology platform offerings.
Alps Group Inc's launch of its Pharmaco-Interaction unit provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 20:12 WIB: out of 150 priced US health-sector stocks, 82 rose and 64 fell. Among notable movers, BNGO rose 4.55% to USD 1.15 with a buy order majority and a typical hold time of 52 days, contrasting with TXG which fell 4.43% to USD 59.30 and INO down 3.73% at USD 1.42, both showing higher sell order activity and differing hold times.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
